Protagonist Therapeutics Inc Stock Nasdaq
Equities
US74366E1029
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- PTS | - |
07-03 | Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000 | CI |
07-03 | Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care | CI |
Sales 2024 * | 292M 0 399M | Sales 2025 * | 93.78M 0 128M | Capitalization | 2.16B 0 2.95B |
---|---|---|---|---|---|
Net income 2024 * | 103M - 141M | Net income 2025 * | -34M - -46.48M | EV / Sales 2024 * | 5.43 x |
Net cash position 2024 * | 572M 0 781M | Net cash position 2025 * | 695M 0 951M | EV / Sales 2025 * | 15.6 x |
P/E ratio 2024 * |
24.1
x | P/E ratio 2025 * |
-26.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.02% |
Latest transcript on Protagonist Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 67 | 08-11-30 |
Asif Ali
DFI | Director of Finance/CFO | 50 | 22-04-17 |
Chief Tech/Sci/R&D Officer | - | 17-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lewis Williams
BRD | Director/Board Member | 74 | 17-06-07 |
Harold Selick
CHM | Chairman | 69 | 09-01-31 |
Daniel Swisher
BRD | Director/Board Member | 61 | 23-10-25 |
1st Jan change | Capi. | |
---|---|---|
+27.34% | 46.56B | |
+45.38% | 41.67B | |
+0.12% | 41.16B | |
+32.58% | 32.4B | |
+20.79% | 28.18B | |
-6.35% | 28.1B | |
+48.94% | 14.52B | |
+48.30% | 13.74B | |
+3.09% | 12.17B |